Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr:114:103998.
doi: 10.1016/j.drugpo.2023.103998. Epub 2023 Mar 6.

"You'll come in and dose even in a global pandemic": A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic

Anna Conway  1 , Carla Treloar  2 , Sione Crawford  3 , Louisa Degenhardt  4 , Gregory J Dore  5 , Michael Farrell  4 , Jeremy Hayllar  6 , Jason Grebely  5 , Alison D Marshall  7
Affiliations

"You'll come in and dose even in a global pandemic": A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic

Anna Conway et al. Int J Drug Policy. 2023 Apr.

Abstract

Background: Opioid agonist treatment (OAT) improves multiple health and social outcomes, yet requirements to attend for supervised dosing can be burdensome and stigmatising. The COVID-19 pandemic and associated restrictions threatened continuity of care and the wellbeing of people receiving OAT, risking a parallel health crisis. This study sought to understand how adaptations in the complex system of OAT provision impacted and responded to risk environments of people receiving OAT during the COVID-19 pandemic.

Methods: The analysis draws on semi-structured interviews with 40 people receiving and 29 people providing OAT located across Australia. The study considered the risk environments that produce COVID-19 transmission, treatment (non-)adherence, and adverse events for people receiving OAT. Drawing on theories of risk environments and complex adaptive systems, data were coded and analysed to understand how adaptations to the typically rigid system of OAT provision impacted and responded to risk environments during the COVID-19 pandemic.

Results: During COVID-19, the complex system of OAT provision demonstrated possibilities for responsive adaptation to the entangled features of risk environments of people receiving OAT. Structural stigma was evident in the services which stayed rigid during the pandemic, requiring people to attend for daily supervised dosing and risking fracturing therapeutic relationships. In parallel, there were several examples of services developing enabling environments by offering flexible care through increased takeaways, treatment subsidies, and home delivery.

Conclusions: Rigidity in the delivery of OAT has been an impediment to achieving health and wellbeing over past decades. To sustain health-promoting environments for people receiving OAT, the wider impacts of the complex system should be acknowledged beyond narrowly defined outcomes relating solely to the medication. Centring people receiving OAT in their own care plans will ensure adaptations in the complex system of OAT provision are responsive to the individual's risk environment.

Keywords: Drug users; Injecting; PWID; Risk environment; SARS-CoV-2; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations of Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CT has received speaker fees from Abbvie and Gilead and has received a research grant from Merck outside the submitted work. SC has received speaker fees from Abbvie outside the submitted work. JG is a consultant/advisor and has received research grants from AbbVie, Camurus, Cepheid, Gilead, Hologic, Indivior, and Merck outside the submitted work. GJD has received research grant funding from Gilead and Abbvie. In the past three years, MF and LD have received funding from Indivior, and Seqirus for studies of new opioid medications in Australia. AC and ADM have nothing to disclose.

References

    1. Amiri S., Lutz R., Socías E., McDonell M.G., Roll J.M., Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. Journal of Substance Abuse Treatment. 2018;93(June):26–30. - PubMed
    1. Arunogiri S., Lintzeris N. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. Journal of Substance Abuse Treatment. 2020;124(108221) doi: 10.1016/j.jsat.2020.108221. - DOI - PMC - PubMed
    1. Australian Institute of Health and Welfare. National opioid pharmacotherapy statistics annual data collection [Internet]. (2022). [cited 2022 Jul 6]. Available from: https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/na....
    1. Benyamina A. The current status of opioid maintenance treatment in France: A survey of physicians, patients, and out-of-treatment opioid users. International Journal of General Medicine. 2014;7:449–457. doi: 10.2147/IJGM.S61014. - DOI - PMC - PubMed
    1. Bourgois P. Disciplining addictions: The bio-politics of methadone and heroin in the U.S. culture. Medicine and Psychiatry. 2000;24:165–195. - PubMed

Publication types

Substances